1877329-24-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-methylazetidin-1-ium (1R,4S)-(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate is used as a potential pharmaceutical compound for its possible biological activities and complex structure, which may lead to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, (S)-2-methylazetidin-1-ium (1R,4S)-(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate is used as a potential candidate for the development of new agrochemicals, such as pesticides or herbicides, due to its unique structural properties.
Used in Materials Science:
(S)-2-methylazetidin-1-ium (1R,4S)-(7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate is used as a potential building block in the development of new materials with specific properties, such as improved strength, durability, or chemical resistance, thanks to its complex molecular structure.

Upstream product

• 61380-66-3 ((1R,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid 
• 61380-66-3 [(1R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid 
• 35963-20-3 (R)-10-camphorsulfonic acid 
• 935669-66-2 (S)-tert-butyl 2-methylazetidine-1-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS USEFUL IN INHIBITING KETOHEXOKINASE AND METHODS OF MAKING AND USING THE SAME

The present invention relates to compounds that can act as inhibitors of ketohexokinase (KHK) and that can be useful in the treatment of diseases and/or disorders associated with KHK. In some embodiments, the present invention relates to compounds and com

2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS

The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

2,6-DIAMINO PYRIDINE COMPOUNDS

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

DISUBSTITUTED PYRAZOLE COMPOUNDS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and no

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Two Scalable Syntheses of (S)-2-Methylazetidine

Two orthogonal routes for preparing (S)-2-methylazetidine as a bench stable, crystalline (R)-(-)-CSA salt are presented. One route features the in situ generation and cyclization of a 1,3-bis-triflate to form the azetidine ring, while the second route inv